1. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab
- Author
-
Yasuyuki Sakai, Kazutaka Saito, Toshiki Kijima, Junji Yonese, Hitoshi Masuda, Yasuhisa Fujii, Yukio Kageyama, Hina Yamamoto, Minato Yokoyama, Nobuaki Matsubara, Shota Kusuhara, Soichiro Yoshida, Takeshi Yuasa, Yoh Matsuoka, and Noboru Numao
- Subjects
Adult ,Male ,Urologic Neoplasms ,Cancer Research ,medicine.medical_specialty ,Immune checkpoint inhibitors ,Immunology ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,Metastasis ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Humans ,Immunology and Allergy ,Urothelial cancer ,Molecular Targeted Therapy ,Aged ,Aged, 80 and over ,biology ,business.industry ,C-reactive protein ,Middle Aged ,Prognosis ,medicine.disease ,Kinetics ,C-Reactive Protein ,Treatment Outcome ,Oncology ,Potential biomarkers ,biology.protein ,Biomarker (medicine) ,Female ,business ,Biomarkers ,030215 immunology - Abstract
To assess the prognostic and predictive ability of early C-reactive protein (CRP) kinetics, dynamic changes in CRP levels, in patients with advanced urothelial cancer treated with pembrolizumab. We retrospectively evaluated 97 patients with advanced urothelial cancer treated with pembrolizumab in second-line or later settings. Patients were divided into three early CRP kinetics groups: non-elevated (baseline CRP
- Published
- 2020
- Full Text
- View/download PDF